ABIOMED, Inc. (NASDAQ:ABMD) issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.16, MarketWatch Earnings reports. The business had revenue of $132.80 million during the quarter, compared to analysts’ expectations of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company’s revenue for the quarter was up 28.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.20 EPS.
ABIOMED (NASDAQ:ABMD) traded down $0.33 during trading on Friday, hitting $195.21. 176,400 shares of the company’s stock traded hands, compared to its average volume of 391,739. ABIOMED has a one year low of $103.53 and a one year high of $198.29. The firm has a market cap of $8,631.41, a PE ratio of 125.13, a P/E/G ratio of 2.60 and a beta of 0.23. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20.
In other news, Director Paul Thomas sold 10,000 shares of the stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the transaction, the director now directly owns 12,172 shares in the company, valued at approximately $1,883,130.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Andrew J. Greenfield sold 11,282 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $169.32, for a total transaction of $1,910,268.24. The disclosure for this sale can be found here. Insiders have sold a total of 61,646 shares of company stock worth $10,003,780 over the last ninety days. 7.00% of the stock is owned by corporate insiders.
A number of equities analysts have commented on ABMD shares. Zacks Investment Research upgraded shares of ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price objective for the company in a research report on Monday, October 30th. BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. Piper Jaffray Companies restated a “buy” rating and set a $160.00 price objective on shares of ABIOMED in a research report on Tuesday, August 29th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $195.00 price target on shares of ABIOMED in a report on Wednesday, November 1st. Finally, Jefferies Group LLC increased their price target on shares of ABIOMED from $175.00 to $208.00 and gave the company a “buy” rating in a report on Friday, September 29th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $185.38.
TRADEMARK VIOLATION NOTICE: “ABIOMED, Inc. (ABMD) Posts Earnings Results, Beats Expectations By $0.16 EPS” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/11/13/abiomed-inc-abmd-releases-quarterly-earnings-results-beats-estimates-by-0-16-eps.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.